Acadia Pharmaceuticals

Acadia Pharmaceuticals is one of the...

• Russell 3000.

Acadia Pharmaceuticals is a company listed under the stock ticker ACAD (US).

View the org chart displaying its 31 main executives

Most searched biographies at Acadia Pharmaceuticals

• Stephen Davis, Chief Executive Officer and Director
• Laura Brege, Director
• Edmund Harrigan, Director

Popular executive movements at Acadia Pharmaceuticals

• Elizabeth Thompson has joined the company as Executive Vice President and Head of Research & Development  (posted on April 3 2024).
• Jennifer Rhodes has joined the company as Executive Vice President, Chief Legal Officer and Secretary  (posted on January 31 2024).
• Kimberly Manhard has joined the company as Senior Vice President, Global Strategic Planning and Execution  (posted on January 31 2024).

Click here to view some more movements at Acadia Pharmaceuticals

Create your alert
to follow the executive moves at Acadia Pharmaceuticals.

Acadia Pharmaceuticals has 1,865 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Acadia Pharmaceuticals

• Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development - Acadia Pharmaceuticals
• Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia - Acadia Pharmaceuticals
• Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview - Acadia Pharmaceuticals
• Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024 - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin) - Acadia Pharmaceuticals
• Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Acadia Pharmaceuticals
• View more press releases Close

Social media about Acadia Pharmaceuticals

• Acadia Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Acadia Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Stephen Davis

Call Acadia Pharmaceuticals at +1 858...

View the org chart

Register to receive your alert

Report an error